1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-112732B
    Sparfosic acid trisodium 70962-66-2 ≥98.0%
    Sparfosic acid trisodium is a DNA antimetabolite agent and a potent inhibitor of aspartate transcarbamoyl transferase. Aspartate transcarbamoyl transferase catalyzes the second step of de novo pyrimidine biosynthesis. Sparfosic acid trisodium synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines.
    Sparfosic acid trisodium
  • HY-W040329
    2'-Deoxyadenosine 958-09-8 ≥98.0%
    2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer.
    2'-Deoxyadenosine
  • HY-B2196
    Gastric mucin 84082-64-4
    Gastric mucin is a glycoprotein with natural antibiotic function. Gastric mucin against Helicobacter pylori infection. Gastric mucin effectively scavenges hydroxyl radical. Gastric mucin play a major role in the protection of the gastrointestinal tract from acid, proteases, pathogenic microorganisms, and mechanical trauma.
    Gastric mucin
  • HY-19522
    Seladelpar 851528-79-5 99.75%
    Seladelpar (MBX-8025) is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar can be used for the study of primary biliary cholangitis.
    Seladelpar
  • HY-76542
    Vitamin D2 50-14-6 ≥98.0%
    Vitamin D2 (Ergocalciferol), drived from plant sources or dietary supplements, could be used as supplement of Vitamin D.
    Vitamin D2
  • HY-101986
    BIIE-0246 246146-55-4 ≥99.0%
    BIIE-0246 (AR-H 053591) is a potent and selective NPY2R (neuropeptide Y receptor 2) antagonist with an IC50 value of 15 nM for rat [125I]PYY3-36. BIIE-0246 decreases the expression of p-AKT S473, P-p44/42 MAPK under the NPY-stimulated. BIIE-0246 reduces albuminuria in ADR nephropathy.
    BIIE-0246
  • HY-139201
    Poly-D-lysine hydrobromide (MW 30000-70000) 27964-99-4
    Poly-D-lysine hydrobromide (MW 30000-70000) is a synthetic polymeric substrate and is one of the most widely used substrate in neural cell culture. Poly-D-lysine hydrobromide is a CaSR agonist peptide.
    Poly-D-lysine hydrobromide (MW 30000-70000)
  • HY-17403
    Manidipine dihydrochloride 89226-75-5 99.84%
    Manidipine dihydrochloride is a third-generation, lipophilic, orally active and highly vasoselective calcium channel antagonist (IC50 = 2.6 nM in guinea-pig ventricular cells) and acts as an antihypertensive agent. Manidipine effectively reduces blood pressure as well as improving insulin sensitivity, renal protection, and antiatherosclerotic activity. Manidipine also exerts anti-inflammatory activity mediated by NF-κB and antiviral activity against many flavivirus and negative-strand RNA viruses through the inhibition of calcium channel. Manidipine is widely applied to research of cardiovascular, metabolic disease and infection.
    Manidipine dihydrochloride
  • HY-B0575
    Triamterene 396-01-0 99.90%
    Triamterene blocks epithelial Na+ channel (ENaC) in a voltage-dependent manner, which used as a mild diuretic. Triamterene is an inhibitor of the TGR5 receptor.
    Triamterene
  • HY-N0502
    Mogroside V 88901-36-4 99.76%
    Mogroside V is a the major active constituent of a traditional Chinese medicine Siraitiae Fructus. Mogroside V reduces the intracellular reactive oxygen species (ROS) levels and enhances mitochondrial function. Mogroside V has anti-oxidative, anti-diabetic and anti-carcinogenic effects. Mogroside V can be used for diabetic diseases research.
    Mogroside V
  • HY-N8518
    Malabaricone C 63335-25-1 ≥99.0%
    Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells.
    Malabaricone C
  • HY-N9410
    Lysophosphatidylcholine 18:2 22252-07-9
    Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS). Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment.
    Lysophosphatidylcholine 18:2
  • HY-114365
    UDP-GalNAc disodium 108320-87-2 99.98%
    UDP-GalNAc (UDP-N-acetyl-D-galactosamine) disodium is a sugar nucleotide and a substrate for EpsC115. EpsC115 is a mutant with N-terminal residues 1-115 deleted from the exopolymeric substance (EPS). UDP-GalNAc disodium is a donor substrate for many N-acetylgalactosaminyltransferases, which transfer GalNAc from nucleotide sugars to sugar or peptide acceptors. UDP-GalNAc disodium provides a sugar group donor for glycosylation reactions. UDP-GalNAc disodium can be used in cancer research, such as colorectal and breast cancer.
    UDP-GalNAc disodium
  • HY-157646
    MZ-101 2839908-40-4 98.98%
    MZ-101 (GYS1-IN-2) is an orally active, potent and selective small-molecule glycogen synthase 1 (GYS1) inhibitor with with an IC50 value of 0.041 µM. MZ-101 reduces glycogen concentrations in cells and in mice. MZ-101 can used to study GYS1 -mediated Pompe disease and other glycogen storage diseases.
    MZ-101
  • HY-W012734
    L-Pipecolic acid 3105-95-1 ≥98.0%
    L-Pipecolic acid (H-HoPro-OH) is an oral active metabolite of Lysine and can accumulate in the bodily fluids of infants with autosomal inherited diseases, such as Zellweger syndrome and neonatal adrenal insufficiency. L-Pipecolic acid can promote muscle cell health and growth by enhancing protein synthesis, and plays a role in promoting gut health. L-Pipecolic acid holds promise for research in the fields of metabolic disorders, muscle growth disorders, and intestinal diseases.
    L-Pipecolic acid
  • HY-W015924
    2-Hydroxyisobutyric acid 594-61-6 ≥98.0%
    2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].
    2-Hydroxyisobutyric acid
  • HY-W016814
    (Z)-Aconitic acid 585-84-2 ≥98.0%
    (Z)-Aconitic acid is an orally active glutamate decarboxylase inhibitor. (Z)-Aconitic acid reduces IκB-α phosphorylation. (Z)-Aconitic acid inhibits Antigen-induced arthritis and Monosodium urate (HY-B2130A)-induced gout.
    (Z)-Aconitic acid
  • HY-B0252
    Hydrochlorothiazide 58-93-5 99.46%
    Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
    Hydrochlorothiazide
  • HY-B0489
    Arecoline hydrobromide 300-08-3 ≥98.0%
    Arecoline hydrobromide, a naturally occurring psychoactive alkaloid, is a partial agonist of nicotinic and muscarinic acetylcholine receptor. Arecoline hydrobromide exhibits stimulation, alertness, anxiolysis and anti-parasitic effects. Arecoline hydrobromide also can induce oxidative stress.
    Arecoline hydrobromide
  • HY-N0279
    Cardamonin 18956-16-6 98.38%
    Cardamonin can be found from cardamom, and can target various signaling molecules, transcriptional factors, cytokines and enzymes. Cardamonin can inhibit mTOR, NF-κB, Akt, STAT3, Wnt/β-catenin and COX-2. Cardamonin shows anticancer, anti-inflammatory, antimicrobial and antidiabetic activities.
    Cardamonin
Cat. No. Product Name / Synonyms Application Reactivity